BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 18562739)

  • 1. The PREDICT study: a randomized double-blind comparison of contrast-induced nephropathy after low- or isoosmolar contrast agent exposure.
    Kuhn MJ; Chen N; Sahani DV; Reimer D; van Beek EJ; Heiken JP; So GJ
    AJR Am J Roentgenol; 2008 Jul; 191(1):151-7. PubMed ID: 18562739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contrast-induced nephropathy in patients with chronic kidney disease undergoing computed tomography: a double-blind comparison of iodixanol and iopamidol.
    Barrett BJ; Katzberg RW; Thomsen HS; Chen N; Sahani D; Soulez G; Heiken JP; Lepanto L; Ni ZH; Ni ZH; Nelson R
    Invest Radiol; 2006 Nov; 41(11):815-21. PubMed ID: 17035872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ACTIVE Trial: comparison of the effects on renal function of iomeprol-400 and iodixanol-320 in patients with chronic kidney disease undergoing abdominal computed tomography.
    Thomsen HS; Morcos SK; Erley CM; Grazioli L; Bonomo L; Ni Z; Romano L;
    Invest Radiol; 2008 Mar; 43(3):170-8. PubMed ID: 18301313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease.
    Solomon RJ; Natarajan MK; Doucet S; Sharma SK; Staniloae CS; Katholi RE; Gelormini JL; Labinaz M; Moreyra AE;
    Circulation; 2007 Jun; 115(25):3189-96. PubMed ID: 17562951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of contrast-medium-induced nephropathy in high-risk patients undergoing MDCT--a pooled analysis of two randomized trials.
    Thomsen HS; Morcos SK
    Eur Radiol; 2009 Apr; 19(4):891-7. PubMed ID: 19002467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of contrast-induced nephrotoxicity of iodixanol and iopromide in patients with renal insufficiency undergoing coronary angiography.
    Shin DH; Choi DJ; Youn TJ; Yoon CH; Suh JW; Kim KI; Cho YS; Cho GY; Chae IH; Kim CH
    Am J Cardiol; 2011 Jul; 108(2):189-94. PubMed ID: 21545991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nephrotoxicity of iodixanol versus iopamidol in patients with chronic kidney disease and diabetes mellitus undergoing coronary angiographic procedures.
    Laskey W; Aspelin P; Davidson C; Rudnick M; Aubry P; Kumar S; Gietzen F; Wiemer M;
    Am Heart J; 2009 Nov; 158(5):822-828.e3. PubMed ID: 19853704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the nephrotoxicity of iodixanol in patients with predisposing factors to contrast medium induced nephropathy referred for contrast enhanced computed tomography.
    Sandstede JJ; Roth A; Machann W; Kaupert C; Hahn D
    Eur J Radiol; 2007 Jul; 63(1):120-3. PubMed ID: 17317065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effectiveness of nephroprotection by the selection of contrast media used during vascular interventions in patients with chronic renal failure?].
    Schönefeld E; Höwler S; Osada N; Torsello G
    Zentralbl Chir; 2011 Oct; 136(5):426-30. PubMed ID: 22009540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nephrotoxic effects of iodixanol and iopromide in patients with abnormal renal function receiving N-acetylcysteine and hydration before coronary angiography and intervention: a randomized trial.
    Juergens CP; Winter JP; Nguyen-Do P; Lo S; French JK; Hallani H; Fernandes C; Jepson N; Leung DY
    Intern Med J; 2009 Jan; 39(1):25-31. PubMed ID: 18771430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ionic low-osmolar versus nonionic iso-osmolar contrast media to obviate worsening nephropathy after angioplasty in chronic renal failure patients: the ICON (Ionic versus non-ionic Contrast to Obviate worsening Nephropathy after angioplasty in chronic renal failure patients) study.
    Mehran R; Nikolsky E; Kirtane AJ; Caixeta A; Wong SC; Teirstein PS; Downey WE; Batchelor WB; Casterella PJ; Kim YH; Fahy M; Dangas GD
    JACC Cardiovasc Interv; 2009 May; 2(5):415-21. PubMed ID: 19463464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media.
    McCullough PA; Bertrand ME; Brinker JA; Stacul F
    J Am Coll Cardiol; 2006 Aug; 48(4):692-9. PubMed ID: 16904536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nephrotoxicity of iso-osmolar versus low-osmolar contrast media is equal in low risk patients.
    Feldkamp T; Baumgart D; Elsner M; Herget-Rosenthal S; Pietruck F; Erbel R; Philipp T; Kribben A
    Clin Nephrol; 2006 Nov; 66(5):322-30. PubMed ID: 17140161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of the efficacy and safety of iopamidol-370 and iodixanol-320 in patients undergoing multidetector-row computed tomography.
    Sahani DV; Soulez G; Chen KM; Lepanto L; Xu JR; Nelson RC; Grazioli L; Vanzulli A; Heiken JP;
    Invest Radiol; 2007 Dec; 42(12):856-61. PubMed ID: 18007158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Background fluctuation of kidney function versus contrast-induced nephrotoxicity.
    Bruce RJ; Djamali A; Shinki K; Michel SJ; Fine JP; Pozniak MA
    AJR Am J Roentgenol; 2009 Mar; 192(3):711-8. PubMed ID: 19234268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial.
    Jo SH; Youn TJ; Koo BK; Park JS; Kang HJ; Cho YS; Chung WY; Joo GW; Chae IH; Choi DJ; Oh BH; Lee MM; Park YB; Kim HS
    J Am Coll Cardiol; 2006 Sep; 48(5):924-30. PubMed ID: 16949481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of contrast-induced nephropathy for patients receiving intravenous vs. intra-arterial iodixanol administration.
    Tong GE; Kumar S; Chong KC; Shah N; Wong MJ; Zimmet JM; Wang ZJ; Yee J; Fu Y; Yeh BM
    Abdom Radiol (NY); 2016 Jan; 41(1):91-9. PubMed ID: 26830615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iodixanol: risk of subsequent contrast nephropathy in cancer patients with underlying renal insufficiency undergoing diagnostic computed tomography examinations.
    Cheruvu B; Henning K; Mulligan J; Klippenstein D; Lawrence D; Gurtoo L; Gottlieb RH
    J Comput Assist Tomogr; 2007; 31(4):493-8. PubMed ID: 17882021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective, double-blind, randomized, controlled trial on the efficacy and cardiorenal safety of iodixanol vs. iopromide in patients with chronic kidney disease undergoing coronary angiography with or without percutaneous coronary intervention.
    Nie B; Cheng WJ; Li YF; Cao Z; Yang Q; Zhao YX; Guo YH; Zhou YJ
    Catheter Cardiovasc Interv; 2008 Dec; 72(7):958-65. PubMed ID: 19021282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iso-osmolality versus low-osmolality iodinated contrast medium at intravenous contrast-enhanced CT: effect on kidney function.
    Nguyen SA; Suranyi P; Ravenel JG; Randall PK; Romano PB; Strom KA; Costello P; Schoepf UJ
    Radiology; 2008 Jul; 248(1):97-105. PubMed ID: 18483232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.